Moreover, both Ber and C60-Ber nanocomplex treatment significantly decreased expression of adaptor protein Ruk/CIN85 (Figure 4), which was found to modulate CD44 and CD24 expression levels and to be involved in the maintenance of CSC features in breast cancer cells [39]. This evidence concerns the gene SH3KBP1 and breast carcinoma.